热门出版物 - 学术资源搜索

h5 指数:33
h5 中位数:54

h5 指数是指在过去整整 5 年中所发表文章的 h 指数。h 指在 2018-2022 年间发表的 h 篇文章每篇至少都被引用过 h 次的最大值。隐藏

出版物的 h5 中位数，是指出版物的 h5 指数所涵盖的所有文章获得的引用次数的中位值。隐藏

#11 AIDS & HIV

标题/作者	引用次数	年份
Coronavirus disease 2019 (COVID‐19) outcomes in HIV/AIDS patients: a systematic review TJ Cooper, BL Woodward, S Alom, A Harky HIV Medicine 21 (9), 567-577	210	2020
Sexualized drug use (‘chemsex’) and high‐risk sexual behaviours in HIV‐positive men who have sex with men EL Pufall, M Kall, M Shahmanesh, A Nardone, R Gilson, V Delpech, ... HIV Medicine 19 (4), 261-270	205	2018
Immune deficiency is a risk factor for severe COVID‐19 in people living with HIV C Hoffmann, JL Casado, G Härter, P Vizcarra, A Moreno, D Cattaneo, ... HIV Medicine 22 (5), 372-378	147	2021
Chemsex and new HIV diagnosis in gay, bisexual and other men who have sex with men attending sexual health clinics M Pakianathan, W Whittaker, MJ Lee, J Avery, S Green, B Nathan, ... HIV Medicine 19 (7), 485-490	137	2018
2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0 L Ryom, A Cotter, R De Miguel, C Béguelin, D Podlekareva, JR Arribas, ... HIV Medicine 21 (10), 617-624	132	2020
Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety? A Hill, S Hughes, A Pozniak HIV MEDICINE 19, S30-S30	125	2018
Highlights of the 2017 European AIDS Clinical Society (EACS) Guidelines for the treatment of adult HIV‐positive persons version 9.0 L Ryom, C Boesecke, M Bracchi, J Ambrosioni, A Pozniak, J Arribas, ... HIV Medicine 19 (5), 309-315	102	2018
Towards elimination of HIV transmission, AIDS and HIV‐related deaths in the UK AE Brown, S Nash, N Connor, PD Kirwan, D Ogaz, S Croxford, ... HIV Medicine 19 (8), 505-512	99	2018
Rapid initiation of antiretroviral therapy at HIV diagnosis: definition, process, knowledge gaps MA Boyd, M Boffito, A Castagna, V Estrada HIV Medicine 20, 3-11	75	2019
The world‐wide incidence of Kaposi's sarcoma in the HIV/AIDS era Z Liu, Q Fang, J Zuo, V Minhas, C Wood, T Zhang HIV Medicine 19 (5), 355-364	64	2018
BHIVA/BASHH guidelines on the use of HIV pre-exposure prophylaxis (PrEP) 2018 M Brady, A Rodger, D Asboe, V Cambiano, D Clutterbuck, M Desai, ... HIV medicine 20, s2-s80	59	2019
Towards person‐centred care for people living with HIV: what core outcomes matter, and how might we assess them? A cross‐national multi‐centre qualitative study with key stakeholders K Bristowe, P Clift, R James, J Josh, M Platt, J Whetham, E Nixon, FA Post, ... HIV Medicine 20 (8), 542-554	58	2019
British HIV Association guidelines for the management of HIV in pregnancy and postpartum 2018 Y Gilleece, S Tariq, A Bamford, S Bhagani, L Byrne, E Clarke, ... HIV medicine 20, s2-s85	57	2019
Predictors of CD 4 cell recovery following initiation of antiretroviral therapy among HIV‐1 positive patients with well‐estimated dates of seroconversion OT Stirrup, AJ Copas, AN Phillips, MJ Gill, RB Geskus, G Touloumi, ... HIV Medicine 19 (3), 184-194	56	2018
Chemsex drugs on the rise: a longitudinal analysis of the Swiss HIV Cohort Study from 2007 to 2017 B Hampel, K Kusejko, RD Kouyos, J Böni, M Flepp, M Stöckle, A Conen, ... HIV Medicine 21 (4), 228-239	56	2020
Two‐drug vs. three‐drug combinations for HIV‐1: Do we have enough data to make the switch? S Moreno, CF Perno, PW Mallon, G Behrens, P Corbeau, JP Routy, ... HIV Medicine 20, 2-12	55	2019
Prognosis of coronavirus disease 2019 (COVID-19) in patients with HIV infection in New York City. H Miyashita, T Kuno HIV Medicine 22 (1), e1-e2	54	2020
MicroRNAs and exosomes: key players in HIV pathogenesis J Sadri Nahand, F Bokharaei‐Salim, M Karimzadeh, M Moghoofei, ... HIV Medicine 21 (4), 246-278	52	2020
Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96‐week results from two randomized clinical trials D Hagins, C Orkin, ES Daar, A Mills, C Brinson, E DeJesus, FA Post, ... HIV Medicine 19 (10), 724-733	51	2018
Rates of sustained virological response 12 weeks after the scheduled end of direct‐acting antiviral (DAA)‐based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy? J Bischoff, S Mauss, C Cordes, T Lutz, S Scholten, A Moll, H Jäger, ... HIV Medicine 19 (4), 299-307	48	2018

1 - 20

计算机程序会自动估算并确定日期和引用次数。